Abstract:
34 million people worldwide were living with the Human Immunodeficiency Virus (HIV) by the
end of 2010. Despite significant advances in antiretroviral therapy (ART), drug resistance remains
a major deterrent to successful, enduring treatment. Unplanned interruptions in ART have
negative effects on HIV treatment outcomes including increased morbidity and mortality, as well
as development of drug resistance. Treatment interruptions due to political conflicts, not
infrequent in resource-limited settings, result in disruptions in health care, infrastructure, or
treatment facilities and patient displacement. Such circumstances are ideal bases for ART
resistance development, however there is limited awareness of and data available on the
association between political conflicts and the development of HIV drug resistance. In this review
we identify and discuss this association and review how varying ART half-lives, genetic barriers,
different HIV subtypes, and archived resistance can lead to lack of medication effectiveness upon
post-conflict resumption of care. Optimized ART stopping strategies as well as infrastructural
concerns and stable HIV treatment systems to ensure continuity of care and rapid resumption of
care must be addressed in order to mitigate risks of HIV drug resistance development during and
after political conflicts. Increased awareness of such associations by clinicians as well as
politicians and stakeholders is essential.
